{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["bone remodeling", "cartilage", "disease modifying drugs", "hyaluronic acid", "inflammation", "knee joint", "mesenchymal stem cells", "osteoarthritis", "ozone", "platelet-rich plasma"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "33800057", "DateCompleted": {"Year": "2021", "Month": "05", "Day": "19"}, "DateRevised": {"Year": "2021", "Month": "05", "Day": "19"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2021", "Month": "03", "Day": "07"}], "ELocationID": ["2697", "10.3390/ijms22052697"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "22", "Issue": "5", "PubDate": {"Year": "2021", "Month": "Mar", "Day": "07"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "From Pathogenesis to Therapy in Knee Osteoarthritis: Bench-to-Bedside.", "Abstract": {"AbstractText": ["Osteoarthritis (OA) is currently the most widespread musculoskeletal condition and primarily affects weight-bearing joints such as the knees and hips. Importantly, knee OA remains a multifactorial whole-joint disease, the appearance and progression of which involves the alteration of articular cartilage as well as the synovium, subchondral bone, ligaments, and muscles through intricate pathomechanisms. Whereas it was initially depicted as a predominantly aging-related and mechanically driven condition given its clear association with old age, high body mass index (BMI), and joint malalignment, more recent research identified and described a plethora of further factors contributing to knee OA pathogenesis. However, the pathogenic intricacies between the molecular pathways involved in OA prompted the study of certain drugs for more than one therapeutic target (amelioration of cartilage and bone changes, and synovial inflammation). Most clinical studies regarding knee OA focus mainly on improvement in pain and joint function and thus do not provide sufficient evidence on the possible disease-modifying properties of the tested drugs. Currently, there is an unmet need for further research regarding OA pathogenesis as well as the introduction and exhaustive testing of potential disease-modifying pharmacotherapies in order to structure an effective treatment plan for these patients."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rheumatology and Physiotherapy, \"Grigore T. Popa\" University of Medicine and Pharmacy, 700115 Ia\u015fi, Romania."}], "LastName": "Rezu\u015f", "ForeName": "Elena", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rheumatology and Physiotherapy, \"Grigore T. Popa\" University of Medicine and Pharmacy, 700115 Ia\u015fi, Romania."}], "LastName": "Burlui", "ForeName": "Alexandra", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rheumatology and Physiotherapy, \"Grigore T. Popa\" University of Medicine and Pharmacy, 700115 Ia\u015fi, Romania."}], "LastName": "Cardoneanu", "ForeName": "Anca", "Initials": "A"}, {"Identifier": ["0000-0002-4856-867X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rheumatology and Physiotherapy, \"Grigore T. Popa\" University of Medicine and Pharmacy, 700115 Ia\u015fi, Romania."}], "LastName": "Macovei", "ForeName": "Luana Andreea", "Initials": "LA"}, {"Identifier": ["0000-0001-9868-1999"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Advanced Center for Research and Development in Experimental Medicine (CEMEX), \"Grigore T. Popa\" University of Medicine and Pharmacy, 700454 Ia\u015fi, Romania."}], "LastName": "Tamba", "ForeName": "Bogdan Ionel", "Initials": "BI"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Internal Medicine, \"Grigore T. Popa\" University of Medicine and Pharmacy, 700115 Ia\u015fi, Romania."}], "LastName": "Rezu\u015f", "ForeName": "Ciprian", "Initials": "C"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}, {"RegistryNumber": "0", "NameOfSubstance": "Matrix Metalloproteinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Wnt Proteins"}, {"RegistryNumber": "EC 3.4.22.38", "NameOfSubstance": "CTSK protein, human"}, {"RegistryNumber": "EC 3.4.22.38", "NameOfSubstance": "Cathepsin K"}, {"RegistryNumber": "EC 3.4.24.-", "NameOfSubstance": "ADAMTS Proteins"}], "MeshHeadingList": [{"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "ADAMTS Proteins"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Biological Products"}, {"QualifierName": ["drug effects", "physiology"], "DescriptorName": "Bone Remodeling"}, {"QualifierName": ["drug effects", "physiopathology"], "DescriptorName": "Cartilage, Articular"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Cathepsin K"}, {"QualifierName": [], "DescriptorName": "Diet"}, {"QualifierName": ["physiology"], "DescriptorName": "Exercise"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Matrix Metalloproteinase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Mesenchymal Stem Cell Transplantation"}, {"QualifierName": ["drug therapy", "physiopathology", "therapy"], "DescriptorName": "Osteoarthritis, Knee"}, {"QualifierName": [], "DescriptorName": "Platelet-Rich Plasma"}, {"QualifierName": ["drug therapy", "etiology"], "DescriptorName": "Synovitis"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Wnt Proteins"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Roemer F.W., Kwoh C.K., Hayashi D., Felson D.T., Guermazi A. The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA. Nat. Rev. Rheumatol. 2018;14:372\u2013380. doi: 10.1038/s41584-018-0010-z.", "ArticleIdList": ["10.1038/s41584-018-0010-z", "PMC6008101", "29752462"]}, {"Citation": "Malfait A.-M., Tortorella M.D. The \u201celusive DMOAD\u201d: Aggrecanase inhibition from laboratory to clinic. Clin. Exp. Rheumatol. 2019;37:130\u2013134.", "ArticleIdList": ["31621572"]}, {"Citation": "Castrogiovanni P., Di Rosa M., Ravalli S., Castorina A., Guglielmino C., Imbesi R., Vecchio M., Drago F., Szychlinska M.A., Musumeci G. Moderate Physical Activity as a Prevention Method for Knee Osteoarthritis and the Role of Synoviocytes as Biological Key. Int. J. Mol. Sci. 2019;20:511. doi: 10.3390/ijms20030511.", "ArticleIdList": ["10.3390/ijms20030511", "PMC6387266", "30691048"]}, {"Citation": "Yeap S.S. Current DMOAD options for the treatment of osteoarthritis. Clin. Exp. Rheumatol. 2020;38:802.", "ArticleIdList": ["32141438"]}, {"Citation": "Roman-Blas J.A., Bizzi E., Largo R., Migliore A., Herrero-Beaumont G. An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease. Expert Opin. Pharmacother. 2016;17:1745\u20131756. doi: 10.1080/14656566.2016.1201070.", "ArticleIdList": ["10.1080/14656566.2016.1201070", "27326466"]}, {"Citation": "Rezu\u0219 E., Cardoneanu A., Burlui A., Luca A., Codreanu C., Tamba B.I., Stanciu G.-D., Dima N., B\u0103descu C., Rezu\u0219 C. The Link Between Inflammaging and Degenerative Joint Diseases. Int. J. Mol. Sci. 2019;20:614. doi: 10.3390/ijms20030614.", "ArticleIdList": ["10.3390/ijms20030614", "PMC6386892", "30708978"]}, {"Citation": "Martel-Pelletier J., Raynauld J.-P., Mineau F., Abram F., Paiement P., Delorme P., Pelletier J.-P. Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: An exploratory study. Arthritis Res. 2017;19:169. doi: 10.1186/s13075-017-1377-y.", "ArticleIdList": ["10.1186/s13075-017-1377-y", "PMC5520291", "28728606"]}, {"Citation": "Vreju F.A., Ciurea P.L., Rosu A., Chisalau B.A., Parvanescu C.D., Firulescu S.C., Stiolica A.T., Barbulescu A.L., Dinescu S.C., Dumitrescu C.I., et al. The Effect of glucosamine, chondroitin and harpagophytum procumbens on femoral hyaline cartilage thickness in patients with knee osteoarthritis\u2014An MRI versus ultrasonography study. J. Mind Med. Sci. 2019:162\u2013168. doi: 10.22543/7674.61.P162168.", "ArticleIdList": ["10.22543/7674.61.P162168"]}, {"Citation": "Reginster J., Veronese N. Highly purified chondroitin sulfate: A literature review on clinical efficacy and pharmaco-economic aspects in osteoarthritis treatment. Aging Clin. Exp. Res. 2020;33:37\u201347. doi: 10.1007/s40520-020-01643-8.", "ArticleIdList": ["10.1007/s40520-020-01643-8", "PMC7897612", "32638342"]}, {"Citation": "Lane N., Shidara K., Wise B. Osteoarthritis year in review 2016: Clinical. Osteoarthr. Cartil. 2017;25:209\u2013215. doi: 10.1016/j.joca.2016.09.025.", "ArticleIdList": ["10.1016/j.joca.2016.09.025", "28100423"]}, {"Citation": "United States Food and Drugs Administration.  [(accessed on 11 January 2021)]; Available online:  https://www.fda.gov/regulatory-information/search-fda-guidance-documents/osteoarthritis-structural-endpoints-development-drugs."}, {"Citation": "European Medicines Agency.  [(accessed on 3 January 2021)]; Available online:  https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-used-treatment-osteoarthritis_en.pdf."}, {"Citation": "Fosang A.J., Little C.B. Drug Insight: Aggrecanases as therapeutic targets for osteoarthritis. Nat. Clin. Pract. Rheumatol. 2008;4:420\u2013427. doi: 10.1038/ncprheum0841.", "ArticleIdList": ["10.1038/ncprheum0841", "18577998"]}, {"Citation": "Murphy G., Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: Destruction or re-pair? Nat. Clin. Pract. Rheumatol. 2008;4:128\u2013135. doi: 10.1038/ncprheum0727.", "ArticleIdList": ["10.1038/ncprheum0727", "18253109"]}, {"Citation": "Chow Y.Y., Chin K.-Y. The Role of Inflammation in the Pathogenesis of Osteoarthritis. Mediat. Inflamm. 2020;2020:1\u201319. doi: 10.1155/2020/8293921.", "ArticleIdList": ["10.1155/2020/8293921", "PMC7072120", "32189997"]}, {"Citation": "Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression. Biochim. Biophys. Acta BBA Bioenerg. 2012;1825:29\u201336. doi: 10.1016/j.bbcan.2011.10.001.", "ArticleIdList": ["10.1016/j.bbcan.2011.10.001", "22020293"]}, {"Citation": "Krzeski P., Buckland-Wright C., B\u00e1lint G., Cline G.A., Stoner K., Lyon R., Beary J., Aronstein W.S., Spector T.D. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: A randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res. Ther. 2007;9:R109. doi: 10.1186/ar2315.", "ArticleIdList": ["10.1186/ar2315", "PMC2212568", "17958901"]}, {"Citation": "Drake C.G. Book Review of \u201cTumor Immunology and Cancer Vaccines\u201d. Cancer Investig. 2006;24:657. doi: 10.1080/07357900600896331.", "ArticleIdList": ["10.1080/07357900600896331"]}, {"Citation": "Baragi V.M., Becher G., Bendele A.M., Biesinger R., Bluhm H., Boer J., Deng H., Dodd R., Essers M., Feuerstein T., et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum. 2009;60:2008\u20132018. doi: 10.1002/art.24629.", "ArticleIdList": ["10.1002/art.24629", "19565489"]}, {"Citation": "Pinney J.R., Taylor C., Doan R., Burghardt A.J., Li X., Kim H.T., Ma C.B., Majumdar S. Imaging longitudinal changes in articular cartilage and bone following doxycycline treatment in a rabbit anterior cruciate ligament transection model of osteoarthritis. Magn. Reson. Imaging. 2012;30:271\u2013282. doi: 10.1016/j.mri.2011.09.025.", "ArticleIdList": ["10.1016/j.mri.2011.09.025", "PMC3307548", "22071411"]}, {"Citation": "da Costa B., N\u00fcesch E., Reichenbach S., J\u00fcni P., Rutjes A. Doxycycline for osteoarthritis of the knee or hip. Cochrane Database Syst. Rev. 2012 doi: 10.1002/14651858.CD007323.pub3.", "ArticleIdList": ["10.1002/14651858.CD007323.pub3", "23152242"]}, {"Citation": "Dubail J., Apte S.S. Insights on ADAMTS proteases and ADAMTS-like proteins from mammalian genetics. Matrix Biol. 2015;44\u201346:24\u201337. doi: 10.1016/j.matbio.2015.03.001.", "ArticleIdList": ["10.1016/j.matbio.2015.03.001", "25770910"]}, {"Citation": "Kaushal G.P., Shah S.V. The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAM family. J. Clin. Investig. 2000;105:1335\u20131337. doi: 10.1172/JCI10078.", "ArticleIdList": ["10.1172/JCI10078", "PMC315473", "10811839"]}, {"Citation": "Little C.B., Meeker C.T., Golub S.B., Lawlor K.E., Farmer P.J., Smith S.M., Fosang A.J. Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J. Clin. Investig. 2008;118:3812. doi: 10.1172/JCI30765C1.", "ArticleIdList": ["10.1172/JCI30765C1", "PMC1866253", "17510707"]}, {"Citation": "Larkin J., Lohr T.A., Elefante L., Shearin J., Matico R., Su J.-L., Xue Y., Liu F., Genell C., Miller R.E., et al. Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthr. Cartil. 2015;23:1254\u20131266. doi: 10.1016/j.joca.2015.02.778.", "ArticleIdList": ["10.1016/j.joca.2015.02.778", "PMC4516626", "25800415"]}, {"Citation": "Chiusaroli R., Visentini M., Galimberti C., Casseler C., Mennuni L., Covaceuszach S., Lanza M., Ugolini G., Caselli G., Rovati L., et al. Targeting of ADAMTS5\u2019s ancillary domain with the recombinant mAb CRB0017 ameliorates disease progression in a spontaneous murine model of osteoarthritis. Osteoarthr. Cartil. 2013;21:1807\u20131810. doi: 10.1016/j.joca.2013.08.015.", "ArticleIdList": ["10.1016/j.joca.2013.08.015", "23954517"]}, {"Citation": "Huang Z., Ding C., Li T., Yu S. Current status and future prospects for disease modification in osteoarthritis. Rheumatology. 2017;57(Suppl. S4):iv108\u2013iv123. doi: 10.1093/rheumatology/kex496.", "ArticleIdList": ["10.1093/rheumatology/kex496", "29272498"]}, {"Citation": "Chockalingam P., Sun W., Rivera-Bermudez M., Zeng W., Dufield D., Larsson S., Lohmander L., Flannery C., Glasson S., Georgiadis K., et al. Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthr. Cartil. 2011;19:315\u2013323. doi: 10.1016/j.joca.2010.12.004.", "ArticleIdList": ["10.1016/j.joca.2010.12.004", "21163358"]}, {"Citation": "Chen P., Zhu S., Wang Y., Mu Q., Wu Y., Xia Q., Zhang X., Sun H., Tao J., Hu H., et al. The amelioration of cartilage degeneration by ADAMTS-5 inhibitor delivered in a hyaluronic acid hydrogel. Biomaterials. 2014;35:2827\u20132836. doi: 10.1016/j.biomaterials.2013.12.076.", "ArticleIdList": ["10.1016/j.biomaterials.2013.12.076", "24424207"]}, {"Citation": "Clement-Lacroix P., Little C., Meurisse S., Blanqu\u00e9 R., Mollat P., Brebion F., Gosmini R., De Ceuninck F., Botez I., Lepescheux L., et al. GLPG1972: A potent, selective, orally available adamts-5 inhibitor for the treatment of OA. Osteoarthr. Cartil. 2017;25:S58\u2013S59. doi: 10.1016/j.joca.2017.02.106.", "ArticleIdList": ["10.1016/j.joca.2017.02.106"]}, {"Citation": "Alcaraz M.J., Guill\u00e9n M.I., Ferr\u00e1ndiz M.L. Emerging therapeutic agents in osteoarthritis. Biochem. Pharmacol. 2019;165:4\u201316. doi: 10.1016/j.bcp.2019.02.034.", "ArticleIdList": ["10.1016/j.bcp.2019.02.034", "30826327"]}, {"Citation": "Wang Y., Fan X., Xing L., Tian F. Wnt signaling: A promising target for osteoarthritis therapy. Cell Commun. Signal. 2019;17:1\u201314. doi: 10.1186/s12964-019-0411-x.", "ArticleIdList": ["10.1186/s12964-019-0411-x", "PMC6697957", "31420042"]}, {"Citation": "Liu S., Yang H., Shuan L., Zhang M. Sirt1 regulates apoptosis and extracellular matrix degradation in resveratrol\u2011treated osteoarthritis chondrocytes via the Wnt/\u03b2\u2011catenin signaling pathways. Exp. Ther. Med. 2017;14:5057\u20135062. doi: 10.3892/etm.2017.5165.", "ArticleIdList": ["10.3892/etm.2017.5165", "PMC5704318", "29201214"]}, {"Citation": "Zhou Y., Wang T., Hamilton J.L., Chen D. Wnt/\u03b2-catenin Signaling in Osteoarthritis and in Other Forms of Arthritis. Curr. Rheumatol. Rep. 2017;19:1\u20138. doi: 10.1007/s11926-017-0679-z.", "ArticleIdList": ["10.1007/s11926-017-0679-z", "PMC5672801", "28752488"]}, {"Citation": "Lietman C., Wu B., Lechner S., Shinar A., Sehgal M., Rossomacha E., Datta P., Sharma A., Gandhi R., Kapoor M., et al. Inhibition of Wnt/\u03b2-catenin signaling ameliorates osteoarthritis in a murine model of experimental osteoarthritis. JCI Insight. 2018;3 doi: 10.1172/jci.insight.96308.", "ArticleIdList": ["10.1172/jci.insight.96308", "PMC5821202", "29415892"]}, {"Citation": "Deshmukh V., Hu H., Barroga C., Bossard C., Kc S., Dellamary L., Stewart J., Chiu K., Ibanez M., Pedraza M., et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthr. Cartil. 2018;26:18\u201327. doi: 10.1016/j.joca.2017.08.015.", "ArticleIdList": ["10.1016/j.joca.2017.08.015", "28888902"]}, {"Citation": "Seo T., Deshmukh V., Yazici Y. AB0069 LORECIVIVINT (SM04690), an intra-articular, small-molecule CLK/DYRK1A inhibitor that modulates the WNT pathway, as a potential treatment for meniscal injuries. Ann. Rheum. Dis. 2020;79(Suppl. S1):1335. doi: 10.1136/annrheumdis-2020-eular.6454.", "ArticleIdList": ["10.1136/annrheumdis-2020-eular.6454"]}, {"Citation": "Takada K., Zhu D., Bird G., Sukhdeo K., Zhao J., Mani M., Lemieux M., Carrasco D., Ryan J., Horst D., et al. Targeted disruption of the BCL9/-catenin complex inhibits oncogenic WNT signaling. Sci. Transl. Med. 2012;4:148ra117. doi: 10.1126/scitranslmed.3003808.", "ArticleIdList": ["10.1126/scitranslmed.3003808", "PMC3631420", "22914623"]}, {"Citation": "Shin Y., Huh Y.H., Kim K., Kim S., Park K.H., Koh J.-T., Chun J.-S., Ryu J.-H. Low-density lipoprotein receptor\u2013related protein 5 governs Wnt-mediated osteoarthritic cartilage destruction. Arthritis Res. Ther. 2014;16:R37. doi: 10.1186/ar4466.", "ArticleIdList": ["10.1186/ar4466", "PMC3978879", "24479426"]}, {"Citation": "Gao S.-G., Zeng C., Liu J.-J., Tian J., Cheng C., Zhang F.-J., Xiong Y.-L., Pan D., Xiao Y.-B., Lei G.-H. Association between Wnt inhibitory factor-1 expression levels in articular cartilage and the disease severity of patients with osteoarthritis of the knee. Exp. Ther. Med. 2016;11:1405\u20131409. doi: 10.3892/etm.2016.3049.", "ArticleIdList": ["10.3892/etm.2016.3049", "PMC4812149", "27073457"]}, {"Citation": "Deshmukh V., O\u2019Green A., Bossard C., Seo T., Lamangan L., Ibanez M., Ghias A., Lai C., Do L., Cho S., et al. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Osteoarthr. Cartil. 2019;27:1347\u20131360. doi: 10.1016/j.joca.2019.05.006.", "ArticleIdList": ["10.1016/j.joca.2019.05.006", "31132406"]}, {"Citation": "Yazici Y., McAlindon T., Gibofsky A., Lane N., Swearingen C., Tambiah J. Radiographic outcomes were concordant with outcome measures in rheumatology-osteoarthritis research society international (OMERACT-OARSI) strict response: Post-hoc analysis from a phase 2 study of a WNT pathway inhibitor, SM04690, for knee osteoarthritis treatment. Osteoarthr. Cartil. 2018;26:S244\u2013S245. doi: 10.1016/j.joca.2018.02.505.", "ArticleIdList": ["10.1016/j.joca.2018.02.505"]}, {"Citation": "Ghouri A., Conaghan P.G. Update on novel pharmacological therapies for osteoarthritis. Ther. Adv. Musculoskelet. Dis. 2019;11:1759720\u20131986449. doi: 10.1177/1759720X19864492.", "ArticleIdList": ["10.1177/1759720X19864492", "PMC6651659", "31384314"]}, {"Citation": "Ghouri A., Conaghan P.G. Prospects for Therapies in Osteoarthritis. Calcif. Tissue Int. 2020:1\u201312. doi: 10.1007/s00223-020-00672-9.", "ArticleIdList": ["10.1007/s00223-020-00672-9", "32055890"]}, {"Citation": "Manicourt D., Beaulieu A., Garnero P., Peterfy C., Bouisset F., Haemmerle S., Mindeholm L. 229 Effect of treatment with the Cathepsin-K inhibitor, balicatib, on cartilage volume and biochemical markers of bone and cartilage degradation in patients with painful knee osteoarthritis. Osteoarthr. Cartil. 2007;15:C130. doi: 10.1016/S1063-4584(07)61861-5.", "ArticleIdList": ["10.1016/S1063-4584(07)61861-5"]}, {"Citation": "Lindstr\u00f6m E., Rizoska B., Henderson I., Terelius Y., Jerling M., Edenius C., Grabowska U. Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711. J. Transl. Med. 2018;16:1\u201314. doi: 10.1186/s12967-018-1497-4.", "ArticleIdList": ["10.1186/s12967-018-1497-4", "PMC5944028", "29743078"]}, {"Citation": "Conaghan P.G., Bowes M.A., Kingsbury S.R., Brett A., Guillard G., Tunblad K., Rizoska B., Larsson T., Holmgren \u00c5., Manninen A., et al. Six months\u2019 treatment with MIV-711, a novel Cathepsin K inhibitor induces osteoarthritis structure modification: Results from a randomized double-blind placebo-controlled phase IIA trial. Osteoarthr. Cartil. 2018;26:S25\u2013S26. doi: 10.1016/j.joca.2018.02.066.", "ArticleIdList": ["10.1016/j.joca.2018.02.066"]}, {"Citation": "Hunter D., Pike M., Jonas B., Kissin E., Krop J., McAlindon T. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet. Disord. 2010;11:232. doi: 10.1186/1471-2474-11-232.", "ArticleIdList": ["10.1186/1471-2474-11-232", "PMC2958989", "20932341"]}, {"Citation": "Reker D., Kjelgaard-Petersen C.F., Siebuhr A.S., Michaelis M., Gigout A., Karsdal M.A., Ladel C., Bay-Jensen A.C. Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo. J. Transl. Med. 2017;15:1\u201312. doi: 10.1186/s12967-017-1356-8.", "ArticleIdList": ["10.1186/s12967-017-1356-8", "PMC5727954", "29233174"]}, {"Citation": "Lohmander L.S., Hellot S., Dreher D., Krantz E.F.W., Kruger D.S., Guermazi A., Eckstein F. Intraarticular Sprifermin (Recombinant Human Fibroblast Growth Factor 18) in Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2014;66:1820\u20131831. doi: 10.1002/art.38614.", "ArticleIdList": ["10.1002/art.38614", "24740822"]}, {"Citation": "Roemer F.W., Aydemir A., Lohmander L.S., Crema M.D., Marra M.D., Muurahainen N., Felson D.T., Eckstein F., Guermazi A. Structural effects of sprifermin in knee osteoarthritis: A post-hoc analysis on cartilage and non-cartilaginous tissue alterations in a randomized controlled trial. BMC Musculoskelet. Disord. 2016;17:1\u20137. doi: 10.1186/s12891-016-1128-2.", "ArticleIdList": ["10.1186/s12891-016-1128-2", "PMC4938999", "27393009"]}, {"Citation": "Gigout A., Guehring H., Froemel D., Meurer A., Ladel C., Reker D., Bay-Jensen A., Karsdal M., Lindemann S. Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. Osteoarthr. Cartil. 2017;25:1858\u20131867. doi: 10.1016/j.joca.2017.08.004.", "ArticleIdList": ["10.1016/j.joca.2017.08.004", "28823647"]}, {"Citation": "Dahlberg L., Flechsenhar K., Dreher D., Go\u00fbteux S., Jurvelin J. A randomized, double-blind, placebo-controllled, multicenter study of Rhfgf18 administered intraarticularly using single or multiple ascending doses in parients with primary knee osteo-arthritis (OA), scheduled for total knee replacement. Osteoarthr. Cartil. 2011;19:S143. doi: 10.1016/S1063-4584(11)60336-1.", "ArticleIdList": ["10.1016/S1063-4584(11)60336-1"]}, {"Citation": "Hochberg M.C., Guermazi A., Guehring H., Aydemir A., Wax S., Fleuranceau-Morel P., Bihlet A.R., Byrjalsen I., Andersen J.R., Eckstein F. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with Osteoarthritis. JAMA. 2019;322:1360\u20131370. doi: 10.1001/jama.2019.14735.", "ArticleIdList": ["10.1001/jama.2019.14735", "PMC6784851", "31593273"]}, {"Citation": "Pers Y.-M., Rackwitz L., Ferreira R., Pullig O., Delfour C., Barry F., Sensebe L., Casteilla L., Fleury S., Bourin P., et al. Adipose Mesenchymal Stromal Cell-Based Therapy for Severe Osteoarthritis of the Knee: A Phase I Dose-Escalation Trial. STEM CELLS Transl. Med. 2016;5:847\u2013856. doi: 10.5966/sctm.2015-0245.", "ArticleIdList": ["10.5966/sctm.2015-0245", "PMC4922848", "27217345"]}, {"Citation": "Muchedzi T.A., Roberts S.B. A systematic review of the effects of platelet rich plasma on outcomes for patients with knee osteoarthritis and following total knee arthroplasty. Surgeon. 2018;16:250\u2013258. doi: 10.1016/j.surge.2017.08.004.", "ArticleIdList": ["10.1016/j.surge.2017.08.004", "28943099"]}, {"Citation": "Bennell K.L., Hunter D.J., Paterson K.L. Platelet-Rich Plasma for the Management of Hip and Knee Osteoarthritis. Curr. Rheumatol. Rep. 2017;19:24. doi: 10.1007/s11926-017-0652-x.", "ArticleIdList": ["10.1007/s11926-017-0652-x", "28386761"]}, {"Citation": "Huebner K., Frank R.M., Getgood A. Ortho-Biologics for Osteoarthritis. Clin. Sports Med. 2019;38:123\u2013141. doi: 10.1016/j.csm.2018.09.002.", "ArticleIdList": ["10.1016/j.csm.2018.09.002", "30466718"]}, {"Citation": "Davies P.S.E., Graham S.M., Macfarlane R.J., Leonidou A., Mantalaris A., Tsiridis E. Disease-modifying osteoarthritis drugs:in vitroandin vivodata on the development of DMOADs under investigation. Expert Opin. Investig. Drugs. 2013;22:423\u2013441. doi: 10.1517/13543784.2013.770837.", "ArticleIdList": ["10.1517/13543784.2013.770837", "23409708"]}, {"Citation": "Toh W.S., Lai R.C., Hui J.H.P., Lim S.K. MSC exosome as a cell-free MSC therapy for cartilage regeneration: Implications for osteoarthritis treatment. Semin. Cell Dev. Biol. 2017;67:56\u201364. doi: 10.1016/j.semcdb.2016.11.008.", "ArticleIdList": ["10.1016/j.semcdb.2016.11.008", "27871993"]}, {"Citation": "Kim Y., Kwon O., Choi Y., Suh D., Heo D., Koh Y. Comparative matched-pair analysis of the injection versus implantation of mesenchymal stem cells for knee osteoarthritis. Am. J. Sports Med. 2015;43:2738\u20132746. doi: 10.1177/0363546515599632.", "ArticleIdList": ["10.1177/0363546515599632", "26337418"]}, {"Citation": "Jevotovsky D., Alfonso A., Einhorn T., Chiu E. Osteoarthritis and stem cell therapy in humans: A systematic review. Osteoarthr. Cartil. 2018;26:711\u2013729. doi: 10.1016/j.joca.2018.02.906.", "ArticleIdList": ["10.1016/j.joca.2018.02.906", "29544858"]}, {"Citation": "Vega A., Mart\u00edn-Ferrero M.A., Del Canto F., Alberca M., Garc\u00eda V., Munar A., Orozco L., Soler R., Fuertes J.J., Huguet M., et al. Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells. Transplantation. 2015;99:1681\u20131690. doi: 10.1097/TP.0000000000000678.", "ArticleIdList": ["10.1097/TP.0000000000000678", "25822648"]}, {"Citation": "Lee S., Lee S.H., Na H.S., Kwon J.Y., Kim G., Jung K., Cho K., Kim S.A., Go E.J., Park M., et al. The therapeutic effect of STAT3 signaling-suppressed MSC on pain and articular cartilage damage in a rat model of monosodium iodoacetate-induced osteoarthritis. Front. Immunol. 2018;9:2881. doi: 10.3389/fimmu.2018.02881.", "ArticleIdList": ["10.3389/fimmu.2018.02881", "PMC6305125", "30619261"]}, {"Citation": "Madry H., Cucchiarini M. Advances and challenges in gene-based approaches for osteoarthritis. J. Gene Med. 2013;15:343\u2013355. doi: 10.1002/jgm.2741.", "ArticleIdList": ["10.1002/jgm.2741", "24006099"]}, {"Citation": "Wu Y., Lu X., Shen B., Zeng Y. The Therapeutic Potential and Role of miRNA, lncRNA, and circRNA in Osteoarthritis. Curr. Gene Ther. 2019;19:255\u2013263. doi: 10.2174/1566523219666190716092203.", "ArticleIdList": ["10.2174/1566523219666190716092203", "31333128"]}, {"Citation": "Zhang W., Robertson W.B., Zhao J., Chen W., Xu J. Emerging Trend in the Pharmacotherapy of Osteoarthritis. Front. Endocrinol. 2019;10:431. doi: 10.3389/fendo.2019.00431.", "ArticleIdList": ["10.3389/fendo.2019.00431", "PMC6614338", "31312184"]}, {"Citation": "Neogi T. Clinical significance of bone changes in osteoarthritis. Ther. Adv. Musculoskelet. Dis. 2012;4:259\u2013267. doi: 10.1177/1759720X12437354.", "ArticleIdList": ["10.1177/1759720X12437354", "PMC3403249", "22859925"]}, {"Citation": "H\u00fcgle T., Geurts J. What drives osteoarthritis? synovial versus subchondral bone pathology. Rheumatology. 2017;56:1461\u20131471.", "ArticleIdList": ["28003493"]}, {"Citation": "Burr D.B. Anatomy and physiology of the mineralized tissues: Role in the pathogenesis of osteoarthrosis. Osteoarthr. Cartil. 2004;12:20\u201330. doi: 10.1016/j.joca.2003.09.016.", "ArticleIdList": ["10.1016/j.joca.2003.09.016", "14698637"]}, {"Citation": "Day J.S., Ding M., Van Der Linden J.C., Hvid I., Sumner D.R., Weinans H. A decreased subchondral trabecular bone tissue elastic modulus is associated with pre-arthritic cartilage damage. J. Orthop. Res. 2001;19:914\u2013918. doi: 10.1016/S0736-0266(01)00012-2.", "ArticleIdList": ["10.1016/S0736-0266(01)00012-2", "11562141"]}, {"Citation": "Ni G.-X., Zhan L.-Q., Gao M.-Q., Lei L., Zhou Y.-Z., Pan Y.-X. Matrix metalloproteinase-3 inhibitor retards treadmill running-induced cartilage degradation in rats. Arthritis Res. Ther. 2011;13:R192. doi: 10.1186/ar3521.", "ArticleIdList": ["10.1186/ar3521", "PMC3334642", "22114772"]}, {"Citation": "Sanchez C., DeBerg M., Piccardi N., Msika P., Reginster J.-Y., Henrotin Y. Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1\u03b2 and oncostatin M pre-treated non-sclerotic osteoblasts. Osteoarthr. Cartil. 2005;13:979\u2013987. doi: 10.1016/j.joca.2005.03.008.", "ArticleIdList": ["10.1016/j.joca.2005.03.008", "16243232"]}, {"Citation": "Prasadam I., Crawford R., Xiao Y. Aggravation of ADAMTS and Matrix Metalloproteinase Production and Role of ERK1/2 Pathway in the Interaction of Osteoarthritic Subchondral Bone Osteoblasts and Articular Cartilage Chondrocytes\u2014Possible Pathogenic Role in Osteoarthritis. J. Rheumatol. 2012;39:621\u2013634. doi: 10.3899/jrheum.110777.", "ArticleIdList": ["10.3899/jrheum.110777", "22247346"]}, {"Citation": "Bianco D., Todorov A., \u010cengi\u0107 T., Pagenstert G., Sch\u00e4ren S., Netzer C., H\u00fcgle T., Geurts J. Alterations of Subchondral Bone Progenitor Cells in Human Knee and Hip Osteoarthritis Lead to a Bone Sclerosis Phenotype. Int. J. Mol. Sci. 2018;19:475. doi: 10.3390/ijms19020475.", "ArticleIdList": ["10.3390/ijms19020475", "PMC5855697", "29415458"]}, {"Citation": "Zhang R.-K., Li G.-W., Zeng C., Lin C.-X., Huang L.-S., Huang G.-X., Zhao C., Feng S.-Y., Fang H. Mechanical stress contributes to osteoarthritis development through the activation of transforming growth factor beta 1 (TGF-\u03b21) Bone Jt. Res. 2018;7:587\u2013594. doi: 10.1302/2046-3758.711.BJR-2018-0057.R1.", "ArticleIdList": ["10.1302/2046-3758.711.BJR-2018-0057.R1", "PMC6269596", "30581556"]}, {"Citation": "Jung Y.-K., Han M.-S., Park H.-R., Lee E.-J., Jang J.-A., Kim G.-W., Lee S.-Y., Moon D., Han S. Calcium-phosphate complex increased during subchondral bone remodeling affects earlystage osteoarthritis. Sci. Rep. 2018;8:487. doi: 10.1038/s41598-017-18946-y.", "ArticleIdList": ["10.1038/s41598-017-18946-y", "PMC5765022", "29323204"]}, {"Citation": "Loeser R.F., Shanker G. Autocrine stimulation by insulin-like growth factor 1 and insulin-like growth factor 2 mediates chondrocyte survival in vitro. Arthritis Rheum. 2000;43:1552\u20131559. doi: 10.1002/1529-0131(200007)43:7<1552::AID-ANR20>3.0.CO;2-W.", "ArticleIdList": ["10.1002/1529-0131(200007)43:7<1552::AID-ANR20>3.0.CO;2-W", "10902760"]}, {"Citation": "Kennedy O.D., Laudier D.M., Majeska R.J., Sun H.B., Schaffler M.B. Osteocyte apoptosis is required for production of osteoclastogenic signals following bone fatigue in vivo. Bone. 2014;64:132\u2013137. doi: 10.1016/j.bone.2014.03.049.", "ArticleIdList": ["10.1016/j.bone.2014.03.049", "PMC4070223", "24709687"]}, {"Citation": "Li J., Xue J., Jing Y., Wang M., Shu R., Xu H., Xue C., Feng J., Wang P., Bai D. SOST Deficiency Aggravates Osteoarthritis in Mice by Promoting Sclerosis of Subchondral Bone. BioMed Res. Int. 2019;2019:1\u20138. doi: 10.1155/2019/7623562.", "ArticleIdList": ["10.1155/2019/7623562", "PMC6885161", "31828128"]}, {"Citation": "Ganesh T., Laughrey L.E., Niroobakhsh M., Lara-Castillo N. Multiscale finite element modeling of mechanical strains and fluid flow in osteocyte lacunocanalicular system. Bone. 2020;137:115328. doi: 10.1016/j.bone.2020.115328.", "ArticleIdList": ["10.1016/j.bone.2020.115328", "PMC7354216", "32201360"]}, {"Citation": "Dai G., Xiao H., Liao J., Zhou N., Zhao C., Xu W., Xu W., Liang X., Huang W. Osteocyte TGF\u03b21\u2013Smad2/3 is positively associated with bone turnover parameters in sub-chondral bone of advanced osteoarthritis. Int. J. Mol. Med. 2020;46:167\u2013178.", "ArticleIdList": ["PMC7255453", "32319543"]}, {"Citation": "Zhou X., Cao H., Yuan Y., Wu W. Biochemical Signals Mediate the Crosstalk between Cartilage and Bone in Osteoarthritis. BioMed Res. Int. 2020;2020:5720360. doi: 10.1155/2020/5720360.", "ArticleIdList": ["10.1155/2020/5720360", "PMC7165323", "32337258"]}, {"Citation": "Hu S., Mao G., Zhang Z., Wu P., Wen X., Liao W., Zhang Z. MicroRNA-320c inhibits development of osteoarthritis through downregulation of canonical Wnt signaling pathway. Life Sci. 2019;228:242\u2013250. doi: 10.1016/j.lfs.2019.05.011.", "ArticleIdList": ["10.1016/j.lfs.2019.05.011", "31075235"]}, {"Citation": "De Santis M., Di Matteo B., Chisari E., Cincinelli G., Angele P., Lattermann C., Filardo G., Vitale N.D., Selmi C., Kon E. The Role of Wnt Pathway in the Pathogenesis of OA and Its Potential Therapeutic Implications in the Field of Regenerative Medicine. BioMed Res. Int. 2018;2018:1\u20138. doi: 10.1155/2018/7402947.", "ArticleIdList": ["10.1155/2018/7402947", "PMC6205317", "30410938"]}, {"Citation": "Zhao W., Wang T., Luo Q., Chen Y., Leung V.Y.L., Wen C., Shah M.F., Pan H., Chiu K., Cao X., et al. Cartilage degeneration and excessive subchondral bone formation in spontaneous osteoarthritis involves altered TGF-\u03b2 signaling. J. Orthop. Res. 2015;34:763\u2013770. doi: 10.1002/jor.23079.", "ArticleIdList": ["10.1002/jor.23079", "26496668"]}, {"Citation": "Zhang L., Wang P.-E., Ying J., Jin X., Luo C., Xu T., Xu S., Dong R., Xiao L., Tong P., et al. Yougui Pills Attenuate Cartilage Degeneration via Activation of TGF-\u03b2/Smad Signaling in Chondrocyte of Osteoarthritic Mouse Model. Front. Pharmacol. 2017;8:611. doi: 10.3389/fphar.2017.00611.", "ArticleIdList": ["10.3389/fphar.2017.00611", "PMC5591843", "28928664"]}, {"Citation": "Upton A.R., Holding C.A., Dharmapatni A.A.S.S.K., Haynes D.R. The expression of RANKL and OPG in the various grades of osteoarthritic cartilage. Rheumatol. Int. 2012;32:535\u2013540. doi: 10.1007/s00296-010-1733-6.", "ArticleIdList": ["10.1007/s00296-010-1733-6", "21259010"]}, {"Citation": "Zhong M., Carney D.H., Jo H., Boyan B.D., Schwartz Z. Inorganic Phosphate Induces Mammalian Growth Plate Chondrocyte Apoptosis in a Mitochondrial Pathway Involving Nitric Oxide and JNK MAP Kinase. Calcif. Tissue Int. 2011;88:96\u2013108. doi: 10.1007/s00223-010-9433-5.", "ArticleIdList": ["10.1007/s00223-010-9433-5", "21104071"]}, {"Citation": "Nishii T., Tamura S., Shiomi T., Yoshikawa H., Sugano N. Alendronate treatment for hip osteoarthritis: Prospective randomized 2-year trial. Clin. Rheumatol. 2013;32:1759\u20131766. doi: 10.1007/s10067-013-2338-8.", "ArticleIdList": ["10.1007/s10067-013-2338-8", "23881439"]}, {"Citation": "Aitken D., Laslett L.L., Cai G., Hill C., March L., Wluka A.E., Wang Y., Blizzard L., Cicuttini F., Jones G. A protocol for a multicentre, randomised, double-blind, placebo-controlled trial to compare the effect of annual infusions of zoledronic acid to placebo on knee structural change and knee pain over 24 months in knee osteoarthritis patients\u2014ZAP2. BMC Musculoskelet. Disord. 2018;19:217. doi: 10.1186/s12891-018-2143-2.", "ArticleIdList": ["10.1186/s12891-018-2143-2", "PMC6052532", "30021646"]}, {"Citation": "Zhu S., Chen K., Lan Y., Zhang N., Jiang R., Hu J. Alendronate protects against articular cartilage erosion by inhibiting subchondral bone loss in ovariectomized rats. Bone. 2013;53:340\u2013349. doi: 10.1016/j.bone.2012.12.044.", "ArticleIdList": ["10.1016/j.bone.2012.12.044", "23291609"]}, {"Citation": "Bingham C.O., III, Buckland-Wright J.C., Garnero P., Cohen S.B., Dougados M., Adami S., Clauw D.J., Spector T.D., Pelletier J.-P., Raynauld J.-P., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 2006;54:3494\u20133507. doi: 10.1002/art.22160.", "ArticleIdList": ["10.1002/art.22160", "17075851"]}, {"Citation": "Spector T.D., Conaghan P.G., Buckland-Wright J.C., Garnero P., Cline G.A., Beary J.F., Valent D.J., Meyer J.M. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: Results of the BRISK randomized, controlled trial [ISRCTN01928173] Arthritis Res. Ther. 2005;7:R625\u2013R633. doi: 10.1186/ar1716.", "ArticleIdList": ["10.1186/ar1716", "PMC1174954", "15899049"]}, {"Citation": "Laslett L.L., Dor\u00e9 D.A., Quinn S.J., Boon P., Ryan E., Winzenberg T.M., Jones G. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: A randomised controlled trial. Ann. Rheum. Dis. 2012;71:1322\u20131328. doi: 10.1136/annrheumdis-2011-200970.", "ArticleIdList": ["10.1136/annrheumdis-2011-200970", "22355040"]}, {"Citation": "Rossini M., Adami S., Fracassi E., Viapiana O., Orsolini G., Povino M.R., Idolazzi L., Gatti D. Effects of intra-articular clodronate in the treatment of knee osteoarthritis: Results of a double-blind, randomized placebo-controlled trial. Rheumatol. Int. 2015;35:255\u2013263. doi: 10.1007/s00296-014-3100-5.", "ArticleIdList": ["10.1007/s00296-014-3100-5", "25080876"]}, {"Citation": "Reginster J.-Y., Badurski J., Bellamy N., Bensen W., Chapurlat R., Chevalier X., Christiansen C., Genant H., Navarro F., Nasonov E., et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: Results of a double-blind, randomised placebo-controlled trial. Ann. Rheum. Dis. 2013;72:179\u2013186. doi: 10.1136/annrheumdis-2012-202231.", "ArticleIdList": ["10.1136/annrheumdis-2012-202231", "PMC3599139", "23117245"]}, {"Citation": "Yu D.-G., Ding H.-F., Mao Y.-Q., Liu M., Yu B., Zhao X., Wang X.-Q., Li Y., Liu G.-W., Nie S.-B., et al. Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model. Acta Pharmacol. Sin. 2013;34:393\u2013402. doi: 10.1038/aps.2012.167.", "ArticleIdList": ["10.1038/aps.2012.167", "PMC4002491", "23334238"]}, {"Citation": "Pelletier J.-P., Roubille C., Raynauld J.-P., Abram F., Dorais M., Delorme P., Martel-Pelletier J. Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: Reduction in bone marrow lesions protects against cartilage loss. Ann. Rheum. Dis. 2015;74:422\u2013429. doi: 10.1136/annrheumdis-2013-203989.", "ArticleIdList": ["10.1136/annrheumdis-2013-203989", "24297379"]}, {"Citation": "Granholm S., Lundberg P., Lerner U.H. Expression of the calcitonin receptor, calcitonin receptor-like receptor, and receptor activity modifying proteins during osteoclast differentiation. J. Cell. Biochem. 2008;104:920\u2013933. doi: 10.1002/jcb.21674.", "ArticleIdList": ["10.1002/jcb.21674", "18384073"]}, {"Citation": "Nielsen R., Bay-Jensen A.-C., Byrjalsen I., Karsdal M. Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover. Osteoarthr. Cartil. 2011;19:466\u2013473. doi: 10.1016/j.joca.2011.01.008.", "ArticleIdList": ["10.1016/j.joca.2011.01.008", "21251986"]}, {"Citation": "Karsdal M., Byrjalsen I., Alexandersen P., Bihlet A., Andersen J., Riis B., Bay-Jensen A., Christiansen C. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: Results from two phase 3 trials. Osteoarthr. Cartil. 2015;23:532\u2013543. doi: 10.1016/j.joca.2014.12.019.", "ArticleIdList": ["10.1016/j.joca.2014.12.019", "25582279"]}, {"Citation": "EMA  European Medicines Agency Recommends Limiting Long-Term Use of Calcitonin Medicines 2012.  [(accessed on 3 January 2021)]; Available online:  https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-recommends-limiting-long-term-use-calcitonin-medicines_en.pdf."}, {"Citation": "McDougall J.J., Schuelert N., Bowyer J. Cathepsin K inhibition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis. Osteoarthr. Cartil. 2010;18:1355\u20131357. doi: 10.1016/j.joca.2010.07.014.", "ArticleIdList": ["10.1016/j.joca.2010.07.014", "20692355"]}, {"Citation": "Hayami T., Zhuo Y., Wesolowski G.A., Pickarski M., Duong L.T. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone. 2012;50:1250\u20131259. doi: 10.1016/j.bone.2012.03.025.", "ArticleIdList": ["10.1016/j.bone.2012.03.025", "22484689"]}, {"Citation": "Lindstr\u00f6m E., Rizoska B., Tunblad K., Edenius C., Bendele A.M., Maul D., Larson M., Shah N., Otto V.Y., Jerome C., et al. The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis. J. Transl. Med. 2018;16:56. doi: 10.1186/s12967-018-1425-7.", "ArticleIdList": ["10.1186/s12967-018-1425-7", "PMC5845353", "29523155"]}, {"Citation": "Karsdal M., Michaelis M., Ladel C., Siebuhr A., Bihlet A., Andersen J., Guehring H., Christiansen C., Bay-Jensen A., Kraus V. Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: Lessons learned from failures and opportunities for the future. Osteoarthr. Cartil. 2016;24:2013\u20132021. doi: 10.1016/j.joca.2016.07.017.", "ArticleIdList": ["10.1016/j.joca.2016.07.017", "27492463"]}, {"Citation": "Vortkamp A., Lee K., Lanske B., Segre G.V., Kronenberg H.M., Tabin C.J. Regulation of Rate of Cartilage Differentiation by Indian Hedgehog and PTH-Related Protein. Science. 1996;273:613\u2013622. doi: 10.1126/science.273.5275.613.", "ArticleIdList": ["10.1126/science.273.5275.613", "8662546"]}, {"Citation": "Sampson E.R., Hilton M.J., Tian Y., Chen D., Schwarz E.M., Mooney R.A., Bukata S.V., O\u2019Keefe R.J., Awad H., Puzas J.E., et al. Teriparatide as a Chondroregenerative Therapy for Injury-Induced Osteoarthritis. Sci. Transl. Med. 2011;3:101ra93. doi: 10.1126/scitranslmed.3002214.", "ArticleIdList": ["10.1126/scitranslmed.3002214", "PMC3208271", "21937758"]}, {"Citation": "Bellido M., Lugo L., Roman-Blas J.A., Casta\u00f1eda S., Calvo E., Largo R., Herrero-Beaumont G. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. Osteoarthr. Cartil. 2011;19:1228\u20131236. doi: 10.1016/j.joca.2011.07.003.", "ArticleIdList": ["10.1016/j.joca.2011.07.003", "21820069"]}, {"Citation": "Wu M., Chen G., Li Y.-P. TGF-\u03b2 and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 2016;4:16009. doi: 10.1038/boneres.2016.9.", "ArticleIdList": ["10.1038/boneres.2016.9", "PMC4985055", "27563484"]}, {"Citation": "Shen J., Li S., Chen D. TGF-\u03b2 signaling and the development of osteoarthritis. Bone Res. 2014;2:14002. doi: 10.1038/boneres.2014.2.", "ArticleIdList": ["10.1038/boneres.2014.2", "PMC4274935", "25541594"]}, {"Citation": "Xie L., Tintani F., Wang X., Li F., Zhen G., Qiu T., Wan M., Crane J., Chen Q., Cao X. Systemic neutralization of TGF-\u03b2 attenuates osteoarthritis. Ann. N. Y. Acad. Sci. 2016;1376:53\u201364. doi: 10.1111/nyas.13000.", "ArticleIdList": ["10.1111/nyas.13000", "PMC4970979", "26837060"]}, {"Citation": "Zhen G., Wen C., Jia X., Li Y., Crane J.L., Mears S.C., Askin F.B., Frassica F.J., Chang W., Yao J., et al. Inhibition of TGF-\u03b2 signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat. Med. 2013;19:704\u2013712. doi: 10.1038/nm.3143.", "ArticleIdList": ["10.1038/nm.3143", "PMC3676689", "23685840"]}, {"Citation": "Rowe P., Kumagai Y., Gutierrez G., Garrett I., Blacher R., Rosen D., Cundy J., Navvab S., Chen D., Drezner M., et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone. 2004;34:303\u2013319. doi: 10.1016/j.bone.2003.10.005.", "ArticleIdList": ["10.1016/j.bone.2003.10.005", "PMC3357088", "14962809"]}, {"Citation": "McGuire D., Lane N., Segal N., Metyas S., Barthel H., Miller M., Rosen D., Kumagai Y. TPX-100 leads to marked, sustained improvements in subjects with knee osteoarthritis: Pre-clinical rationale and results of a controlled clinical trial. Osteoarthr. Cartil. 2018;26:S243. doi: 10.1016/j.joca.2018.02.502.", "ArticleIdList": ["10.1016/j.joca.2018.02.502"]}, {"Citation": "Nagai T., Sato M., Kutsuna T., Kokubo M., Ebihara G., Ohta N., Mochida J. Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair. Arthritis Res. Ther. 2010;12:R178. doi: 10.1186/ar3142.", "ArticleIdList": ["10.1186/ar3142", "PMC2991009", "20868495"]}, {"Citation": "Cui Z., Crane J., Xie H., Jin X., Zhen G., Li C., Xie L., Wang L., Bian Q., Qiu T., et al. Halofuginone attenuates osteoarthritis by inhibition of TGF-\u03b2 activity and H-type vessel formation in subchondral bone. Ann. Rheum. Dis. 2015;75:1714\u20131721. doi: 10.1136/annrheumdis-2015-207923.", "ArticleIdList": ["10.1136/annrheumdis-2015-207923", "PMC5013081", "26470720"]}, {"Citation": "Lu J., Zhang H., Cai D., Zeng C., Lai P., Shao Y., Fang H., Li D., Ouyang J., Zhao C., et al. Positive-Feedback Regulation of Subchondral H-Type Vessel Formation by Chondrocyte Promotes Osteoarthritis Development in Mice. J. Bone Miner. Res. 2018;33:909\u2013920. doi: 10.1002/jbmr.3388.", "ArticleIdList": ["10.1002/jbmr.3388", "29329496"]}, {"Citation": "Walsh D.A., McWilliams D.F., Turley M.J., Dixon M.R., Frans\u00e8s R.E., Mapp P.I., Wilson D. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology. 2010;49:1852\u20131861. doi: 10.1093/rheumatology/keq188.", "ArticleIdList": ["10.1093/rheumatology/keq188", "PMC2936950", "20581375"]}, {"Citation": "Xie H., Cui Z., Wang L., Xia Z., Hu Y., Xian L., Li C., Xie L., Crane J., Wan M., et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat. Med. 2014;20:1270\u20131278. doi: 10.1038/nm.3668.", "ArticleIdList": ["10.1038/nm.3668", "PMC4224644", "25282358"]}, {"Citation": "Schnitzer T.J., Ekman E.F., Spierings E.L.H., Greenberg H.S., Smith M.D., Brown M.T., West C.R., Verburg K.M. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann. Rheum. Dis. 2015;74:1202\u20131211. doi: 10.1136/annrheumdis-2013-204905.", "ArticleIdList": ["10.1136/annrheumdis-2013-204905", "24625625"]}, {"Citation": "Hochberg M.C., Tive L.A., Abramson S.B., Vignon E., Verburg K.M., West C.R., Smith M.D., Hungerford D.S. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. Arthritis Rheumatol. 2016;68:382\u2013391. doi: 10.1002/art.39492.", "ArticleIdList": ["10.1002/art.39492", "26554876"]}, {"Citation": "Clinicaltrials.gov  Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) for Treatment of Adults with Pain from Osteoarthritis of the Knee or Hip (FACT OA2). Re-generon Pharmaceuticals.  [(accessed on 5 January 2021)];2018  Available online:  https://clinicaltrials.gov/ct2/show/NCT03304379."}, {"Citation": "Yang C.Y., Chanalaris A., Troeberg L. ADAMTS and ADAM metalloproteinases in osteoarthritis\u2014Looking beyond the \u2018usual suspects\u2019. Osteoarthr. Cartil. 2017;25:1000\u20131009. doi: 10.1016/j.joca.2017.02.791.", "ArticleIdList": ["10.1016/j.joca.2017.02.791", "PMC5473942", "28216310"]}, {"Citation": "Atukorala I., Kwoh C.K., Guermazi A., Roemer F.W., Boudreau R.M., Hannon M.J., Hunter D.J. Synovitis in knee osteoarthritis: A precursor of disease? Ann. Rheum. Dis. 2016;75:390\u2013395. doi: 10.1136/annrheumdis-2014-205894.", "ArticleIdList": ["10.1136/annrheumdis-2014-205894", "PMC4916836", "25488799"]}, {"Citation": "Schnitzer T.J., Easton R., Pang S., Levinson D.J., Pixton G., Viktrup L., Davignon I., Brown M.T., West C.R., Verburg K.M. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: A randomized clinical trial. JAMA. 2019;322:37\u201348. doi: 10.1001/jama.2019.8044.", "ArticleIdList": ["10.1001/jama.2019.8044", "PMC6613301", "31265100"]}, {"Citation": "Dakin P., DiMartino S.J., Gao H., Maloney J., Kivitz A.J., Schnitzer T.J., Stahl N., Yancopoulos G.D., Geba G.P. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Arthritis Rheumatol. 2019;71:1824\u20131834. doi: 10.1002/art.41012.", "ArticleIdList": ["10.1002/art.41012", "PMC6900077", "31207169"]}, {"Citation": "Kim J.-R., Yoo J.J., Kim H.A. Therapeutics in Osteoarthritis Based on an Understanding of Its Molecular Pathogenesis. Int. J. Mol. Sci. 2018;19:674. doi: 10.3390/ijms19030674.", "ArticleIdList": ["10.3390/ijms19030674", "PMC5877535", "29495538"]}, {"Citation": "Yu S.P.-C., Hunter D.J. Emerging drugs for the treatment of knee osteoarthritis. Expert Opin. Emerg. Drugs. 2015;20:361\u2013378. doi: 10.1517/14728214.2015.1037275.", "ArticleIdList": ["10.1517/14728214.2015.1037275", "25865855"]}, {"Citation": "Siebuhr A.S., Bay-Jensen A.C., Jordan J.M., Kjelgaard-Petersen C.F., Christiansen C., Abramson S.B., Attur M., Berenbaum F., Kraus V., Karsdal M.A. Inflammation (or synovitis)-driven osteoarthritis: An opportunity for personalizing prognosis and treatment? Scand. J. Rheumatol. 2015;45:87\u201398. doi: 10.3109/03009742.2015.1060259.", "ArticleIdList": ["10.3109/03009742.2015.1060259", "26484849"]}, {"Citation": "Wang J. Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial. J. Int. Med Res. 2017;46:326\u2013334. doi: 10.1177/0300060517723182.", "ArticleIdList": ["10.1177/0300060517723182", "PMC6011328", "28840750"]}, {"Citation": "Ohtori S., Orita S., Yamauchi K., Eguchi Y., Ochiai N., Kishida S., Kuniyoshi K., Aoki Y., Nakamura J., Ishikawa T., et al. Efficacy of Direct Injection of Etanercept into Knee Joints for Pain in Moderate and Severe Knee Osteoarthritis. Yonsei Med. J. 2015;56:1379\u20131383. doi: 10.3349/ymj.2015.56.5.1379.", "ArticleIdList": ["10.3349/ymj.2015.56.5.1379", "PMC4541670", "26256983"]}, {"Citation": "Chevalier X., Goupille P., Beaulieu A.D., Burch F.X., Bensen W.G., Conrozier T., Loeuille D., Kivitz A.J., Silver D., Appleton B.E. Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009;61:344\u2013352. doi: 10.1002/art.24096.", "ArticleIdList": ["10.1002/art.24096", "19248129"]}, {"Citation": "Wang S.X., Abramson S.B., Attur M., Karsdal M.A., Preston R.A., Lozada C.J., Kosloski M.P., Hong F., Jiang P., Saltarelli M.J., et al. Safety, tolerability, and pharmacodynamics of an anti-interleukin-1\u03b1/\u03b2 dual variable domain immuno-globulin in patients with osteoarthritis of the knee: A randomized phase 1 study. Osteoarthr. Cartil. 2017;25:1952\u20131961. doi: 10.1016/j.joca.2017.09.007.", "ArticleIdList": ["10.1016/j.joca.2017.09.007", "28964890"]}, {"Citation": "Migliore A., Paoletta M., Moretti A., Liguori S., Iolascon G. The perspectives of intra-articular therapy in the management of osteoarthritis. Expert Opin. Drug Deliv. 2020;17:1213\u20131226. doi: 10.1080/17425247.2020.1783234.", "ArticleIdList": ["10.1080/17425247.2020.1783234", "32543240"]}, {"Citation": "Gibofsky A., Hochberg M.C., Jaros M.J., Young C.L. Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: A 12 week, phase 3 study. Curr. Med Res. Opin. 2014;30:1883\u20131893. doi: 10.1185/03007995.2014.946123.", "ArticleIdList": ["10.1185/03007995.2014.946123", "25050589"]}, {"Citation": "Philp A.M., Davis E.T., Jones S.W. Developing anti-inflammatory therapeutics for patients with osteoarthritis. Rheumatology. 2016;56:869\u2013881. doi: 10.1093/rheumatology/kew278.", "ArticleIdList": ["10.1093/rheumatology/kew278", "27498352"]}, {"Citation": "Gallelli L., Galasso O., Falcone D., Southworth S., Greco M., Ventura V., Romualdi P., Corigliano A., Terracciano R., Savino R., et al. The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes, synovial fluid cytokine concentration and signal transduction pathways in knee osteoarthritis. A randomized open label trial. Osteoarthr. Cartil. 2013;21:1400\u20131408. doi: 10.1016/j.joca.2013.06.026.", "ArticleIdList": ["10.1016/j.joca.2013.06.026", "23973155"]}, {"Citation": "Lim C.C., Ang A.T.W., Kadir H.B.A., Lee P.H., Goh B.Q., Harikrishnan S., Kwek J.L., Gan S.S.W., Choo J.C.J., Tan N.C. Short-Course Systemic and Topical Non-Steroidal Anti-Inflammatory Drugs: Impact on Adverse Renal Events in Older Adults with Co-Morbid Disease. Drugs Aging. 2021;38:147\u2013156. doi: 10.1007/s40266-020-00824-4.", "ArticleIdList": ["10.1007/s40266-020-00824-4", "33251568"]}, {"Citation": "Jovanovic D.V., Fernandes J.C., Martel-Pelletier J., Jolicoeur F.C., Reboul P., Laufer S., Tries S., Pelletier J.P. In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1\u03b2 synthesis. Arthritis Rheum. 2001;44:2320\u20132330. doi: 10.1002/1529-0131(200110)44:10<2320::AID-ART394>3.0.CO;2-P.", "ArticleIdList": ["10.1002/1529-0131(200110)44:10<2320::AID-ART394>3.0.CO;2-P", "11665972"]}, {"Citation": "Raynauld J.P., Martel-Pelletier J., Bias P., Laufer S., Haraoui B., Choquette D., Beaulieu A.D., Abram F., Dorais M., Vignon E., et al. Protective effects of licofelone, a 5-lipoxygenase and cy-clo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: A first multicentre clinical trial using quanti-tative MRI. Ann. Rheum. Dis. 2009;68:938\u2013947. doi: 10.1136/ard.2008.088732.", "ArticleIdList": ["10.1136/ard.2008.088732", "18653484"]}, {"Citation": "Vaishya R., Pandit R., Agarwal A.K., Vijay V. Intra-articular hyaluronic acid is superior to steroids in knee osteoarthritis: A comparative, randomized study. J. Clin. Orthop. Trauma. 2017;8:85\u201388. doi: 10.1016/j.jcot.2016.09.008.", "ArticleIdList": ["10.1016/j.jcot.2016.09.008", "PMC5359523", "28360505"]}, {"Citation": "He W.-W., Kuang M.-J., Zhao J., Sun L., Lu B., Wang Y., Ma J.-X., Ma X.-L. Efficacy and safety of intraarticular hyaluronic acid and corticosteroid for knee osteoarthritis: A meta-analysis. Int. J. Surg. 2017;39:95\u2013103. doi: 10.1016/j.ijsu.2017.01.087.", "ArticleIdList": ["10.1016/j.ijsu.2017.01.087", "28137554"]}, {"Citation": "Mol M.F., Runhaar J., Bos P.K., Dorleijn D.M.J., Vis M., Gussekloo J., Bindels P.J.E., Bierma-Zeinstra S.M.A. Effectiveness of intramuscular gluteal glucocorticoid injection versus intra-articular glucocorticoid injection in knee osteoarthritis: Design of a multicenter randomized, 24 weeks comparative parallel-group trial. BMC Musculoskelet. Disord. 2020;21:1\u20139. doi: 10.1186/s12891-020-03255-9.", "ArticleIdList": ["10.1186/s12891-020-03255-9", "PMC7149870", "32278346"]}, {"Citation": "Samuels J., Pillinger M.H., Jevsevar D., Felson D., Simon L.S. Critical appraisal of intra-articular glucocorticoid injections for symptomatic osteoarthritis of the knee. Osteoarthr. Cartil. 2021;29:8\u201316. doi: 10.1016/j.joca.2020.09.001.", "ArticleIdList": ["10.1016/j.joca.2020.09.001", "32911075"]}, {"Citation": "Hangody L., Szody R., Lukasik P., Zgadzaj W., L\u00e9n\u00e1rt E., Dokoupilova E., Bichovsk D., Berta A., Vasarhelyi G., Ficzere A., et al. Intraarticular injection of a cross-linked sodium hyaluronate combined with triamcinolone hexacetonide (Cingal) to provide symptomatic relief of osteoarthritis of the knee: A randomized, double-blind, placebo-controlled multicenter clinical trial. Cartilage. 2018;9:276\u2013283. doi: 10.1177/1947603517703732.", "ArticleIdList": ["10.1177/1947603517703732", "PMC6042027", "28535076"]}, {"Citation": "Babaei-Ghazani A., Najarzadeh S., Mansoori K., Forogh B., Madani S.P., Ebadi S., Fadavi H.R., Eftekharsadat B. The effects of ultrasound-guided corticosteroid injection compared to oxygen-ozone (O2-O3) injection in patients with knee osteo-arthritis: A randomized controlled trial. Clin. Rheumatol. 2018;37:2517\u20132527. doi: 10.1007/s10067-018-4147-6.", "ArticleIdList": ["10.1007/s10067-018-4147-6", "29796866"]}, {"Citation": "Pelletier J.-P., Raynauld J.-P., Dorais M., Bessette L., Dokoupilova E., Morin F., Pavelka K., Paiement P., Martel-Pelletier J., DISSCO Trial Investigator Group An international, multicentre, double-blind, randomized study (DISSCO): Effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. Rheumatology. 2020;59:3858\u20133868. doi: 10.1093/rheumatology/keaa072.", "ArticleIdList": ["10.1093/rheumatology/keaa072", "PMC7733720", "32521015"]}, {"Citation": "Jung J.H., Kim S.E., Kim H.-J., Park K., Song G.G., Choi S.J. A comparative pilot study of oral diacerein and locally treated diacerein-loaded nanoparticles in a model of osteoarthritis. Int. J. Pharm. 2020;581:119249. doi: 10.1016/j.ijpharm.2020.119249.", "ArticleIdList": ["10.1016/j.ijpharm.2020.119249", "32217157"]}, {"Citation": "Leonidou A., Lepetsos P., Mintzas M., Kenanidis E., Macheras G., Tzetis M., Potoupnis M., Tsiridis E. Inducible nitric oxide synthase as a target for osteoarthritis treatment. Expert Opin. Ther. Targets. 2018;22:299\u2013318. doi: 10.1080/14728222.2018.1448062.", "ArticleIdList": ["10.1080/14728222.2018.1448062", "29504411"]}, {"Citation": "Ahmad N., Ansari M.Y., Haqqi T.M. Role of iNOS in osteoarthritis: Pathological and therapeutic aspects. J. Cell. Physiol. 2020;235:6366\u20136376. doi: 10.1002/jcp.29607.", "ArticleIdList": ["10.1002/jcp.29607", "32017079"]}, {"Citation": "Le Graverand M.-P.H., Clemmer R.S., Redifer P., Brunell R.M., Hayes C.W., Brandt K.D., Abramson S.B., Manning P.T., Miller C.G., Vignon E. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann. Rheum. Dis. 2013;72:187\u2013195. doi: 10.1136/annrheumdis-2012-202239.", "ArticleIdList": ["10.1136/annrheumdis-2012-202239", "23144445"]}, {"Citation": "Jacob G., Shetty V., Shetty S. A study assessing intra-articular PRP vs PRP with HMW HA vs PRP with LMW HA in early knee osteoarthritis. J. Arthrosc. Jt. Surg. 2017;4:65\u201371. doi: 10.1016/j.jajs.2017.08.008.", "ArticleIdList": ["10.1016/j.jajs.2017.08.008"]}, {"Citation": "Cook C.S., Smith P.A. Clinical Update: Why PRP Should Be Your First Choice for Injection Therapy in Treating Osteoarthritis of the Knee. Curr. Rev. Musculoskelet. Med. 2018;11:583\u2013592. doi: 10.1007/s12178-018-9524-x.", "ArticleIdList": ["10.1007/s12178-018-9524-x", "PMC6220006", "30350299"]}, {"Citation": "Saif D.S., Hegazy N.N., Zahran E.S. Evaluating the efficacy of intra-articular injections of platelet rich plasma (PRP) in rheumatoid arthritis patients and its impact on inflammatory cytokines, disease activity and quality of life. Curr. Rheumatol. Rev. 2020;16:1. doi: 10.2174/1573397116666201113090629.", "ArticleIdList": ["10.2174/1573397116666201113090629", "33185167"]}, {"Citation": "Filardo G., Previtali D., Napoli F., Candrian C., Zaffagnini S., Grassi A. PRP injections for the treatment of knee osteoar-thritis: A meta-analysis of randomized controlled trials. Cartilage. 2020 doi: 10.1177/1947603520931170.", "ArticleIdList": ["10.1177/1947603520931170", "32551947"]}, {"Citation": "O\u2019Connell B., Wragg N.M., Wilson S.L. The use of PRP injections in the management of knee osteoarthritis. Cell Tissue Res. 2019;376:143\u2013152. doi: 10.1007/s00441-019-02996-x.", "ArticleIdList": ["10.1007/s00441-019-02996-x", "30758709"]}, {"Citation": "Yin W., Xu H., Sheng J., Xu Z., Xie X., Zhang C. Comparative evaluation of the effects of platelet rich plasma formulations on extracellular matrix formation and the NF \u03baB signaling pathway in human articular chondrocytes. Mol. Med. Rep. 2017;15:2940\u20132948. doi: 10.3892/mmr.2017.6365.", "ArticleIdList": ["10.3892/mmr.2017.6365", "PMC5428536", "28339078"]}, {"Citation": "Simental-Mend\u00eda M., V\u00edlchez-Cavazos J.F., Pe\u00f1a-Mart\u00ednez V.M., Said-Fern\u00e1ndez S., Lara-Arias J., Mart\u00ednez-Rodr\u00edguez H.G. Leukocyte-poor platelet-rich plasma is more effective than the conventional therapy with acetaminophen for the treatment of early knee osteoarthritis. Arch. Orthop. Trauma Surg. 2016;136:1723\u20131732. doi: 10.1007/s00402-016-2545-2.", "ArticleIdList": ["10.1007/s00402-016-2545-2", "27506585"]}, {"Citation": "Tong S., Liu J., Zhang C. Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like syno-viocytes in rheumatoid arthritis. Clin. Exp. Med. 2017;17:441\u2013449. doi: 10.1007/s10238-017-0449-2.", "ArticleIdList": ["10.1007/s10238-017-0449-2", "28120218"]}, {"Citation": "Migliorini F., Driessen A., Quack V., Sippel N., Cooper B., El Mansy Y., Tingart M., Eschweiler J. Comparison between intra-articular infiltrations of placebo, steroids, hyaluronic and PRP for knee osteoarthritis: A Bayesian network meta-analysis. Arch. Orthop. Trauma Surg. 2020:1\u201318. doi: 10.1007/s00402-020-03551-y.", "ArticleIdList": ["10.1007/s00402-020-03551-y", "32725315"]}, {"Citation": "Huang G., Hua S., Yang T., Ma J., Yu W., Chen X. Platelet\u2011rich plasma shows beneficial effects for patients with knee osteoarthritis by suppressing inflammatory factors. Exp. Ther. Med. 2018;15:3096\u20133102. doi: 10.3892/etm.2018.5794.", "ArticleIdList": ["10.3892/etm.2018.5794", "PMC5867452", "29599843"]}, {"Citation": "Xu Z., He Z., Shu L., Li X., Ma M., Ye C. Intra-articular platelet-rich plasma combined with hyaluronic acid injection for knee osteoarthritis is superior to platelet-rich plasma or hyaluronic acid alone in inhibiting inflammation and improving pain and function. Arthrosc. J. Arthrosc. Relat. Surg. 2020 doi: 10.1016/j.arthro.2020.10.013.", "ArticleIdList": ["10.1016/j.arthro.2020.10.013", "33091549"]}, {"Citation": "Nelson F.R., Zvirbulis R.A., Zonca B., Li K.W., Turner S.M., Pasierb M., Wilton P., Martinez-Puig D., Wu W. The effects of an oral preparation containing hyaluronic acid (Oralvisc\u00ae) on obese knee osteoarthritis patients determined by pain, function, bradykinin, leptin, inflammatory cytokines, and heavy water analyses. Rheumatol. Int. 2015;35:43\u201352. doi: 10.1007/s00296-014-3047-6.", "ArticleIdList": ["10.1007/s00296-014-3047-6", "24899570"]}, {"Citation": "Raeissadat S.A., Rayegani S.M., Forogh B., Abadi P.H., Moridnia M., Dehgolan S.R. Intra-articular ozone or hyaluronic acid injection: Which one is superior in patients with knee osteoarthritis? A 6-month randomized clinical trial. J. Pain Res. 2018;11:111. doi: 10.2147/JPR.S142755.", "ArticleIdList": ["10.2147/JPR.S142755", "PMC5757972", "29379312"]}, {"Citation": "Lopes de Jesus C.C., Dos Santos F.C., de Jesus L.M., Monteiro I., Sant\u2019Ana M.S., Trevisani V.F. Comparison between in-tra-articular ozone and placebo in the treatment of knee osteoarthritis: A randomized, double-blinded, placebo-controlled study. PLoS ONE. 2017;12:e0179185. doi: 10.1371/journal.pone.0179185.", "ArticleIdList": ["10.1371/journal.pone.0179185", "PMC5524330", "28738079"]}, {"Citation": "Loeser R., Beavers D., Bay-Jensen A., Karsdal M., Nicklas B., Guermazi A., Hunter D., Messier S. Effects of dietary weight loss with and without exercise on interstitial matrix turnover and tissue inflammation biomarkers in adults with knee osteoarthritis: The Intensive Diet and Exercise for Arthritis trial (IDEA) Osteoarthr. Cartil. 2017;25:1822\u20131828. doi: 10.1016/j.joca.2017.07.015.", "ArticleIdList": ["10.1016/j.joca.2017.07.015", "PMC5650925", "28756278"]}, {"Citation": "Cheragh-Birjandi S., Moghbeli M., Haghighi F., Safdari M.R., Baghernezhad M., Akhavan A., Ganji R. Impact of resistance exercises and nano-curcumin on synovial levels of collagenase and nitric oxide in women with knee osteoarthritis. Transl. Med. Commun. 2020;5:1\u20136. doi: 10.1186/s41231-020-00055-0.", "ArticleIdList": ["10.1186/s41231-020-00055-0"]}, {"Citation": "Manoy P., Yuktanandana P., Tanavalee A., Anomasiri W., Ngarmukos S., Tanpowpong T., Honsawek S. Vitamin D Supplementation Improves Quality of Life and Physical Performance in Osteoarthritis Patients. Nutrients. 2017;9:799. doi: 10.3390/nu9080799.", "ArticleIdList": ["10.3390/nu9080799", "PMC5579593", "28933742"]}, {"Citation": "Gao X.R., Chen Y.S., Deng W. The effect of vitamin D supplementation on knee osteoarthritis: A meta-analysis of ran-domized controlled trials. Int. J. Surg. 2017;46:14\u201320. doi: 10.1016/j.ijsu.2017.08.010.", "ArticleIdList": ["10.1016/j.ijsu.2017.08.010", "28797917"]}, {"Citation": "Wang X., Cicuttini F., Jin X., Wluka A., Han W., Zhu Z., Blizzard L., Antony B., Winzenberg T., Jones G., et al. Knee effusion-synovitis volume measurement and effects of vitamin D supplementation in patients with knee osteoarthritis. Osteoarthr. Cartil. 2017;25:1304\u20131312. doi: 10.1016/j.joca.2017.02.804.", "ArticleIdList": ["10.1016/j.joca.2017.02.804", "28274889"]}, {"Citation": "Thevaranjan N., Puchta A., Schulz C., Naidoo A., Szamosi J., Verschoor C.P., Loukov D., Schenck L.P., Jury J., Foley K.P., et al. Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction. Cell Host Microbe. 2017;21:455\u2013466.e4. doi: 10.1016/j.chom.2017.03.002.", "ArticleIdList": ["10.1016/j.chom.2017.03.002", "PMC5392495", "28407483"]}, {"Citation": "Franceschi C., Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2014;69(Suppl. S1):S4\u2013S9. doi: 10.1093/gerona/glu057.", "ArticleIdList": ["10.1093/gerona/glu057", "24833586"]}, {"Citation": "Tsai J.C., Casteneda G., Lee A., Dereschuk K., Li W.T., Chakladar J., Lombardi A.F., Ongkeko W.M., Chang E.Y. Identification and Characterization of the Intra-Articular Microbiome in the Osteoarthritic Knee. Int. J. Mol. Sci. 2020;21:8618. doi: 10.3390/ijms21228618.", "ArticleIdList": ["10.3390/ijms21228618", "PMC7697780", "33207573"]}, {"Citation": "Szychlinska M.A., Di Rosa M., Castorina A., Mobasheri A., Musumeci G. A correlation between intestinal microbiota dysbiosis and osteoarthritis. Heliyon. 2019;5:e01134. doi: 10.1016/j.heliyon.2019.e01134.", "ArticleIdList": ["10.1016/j.heliyon.2019.e01134", "PMC6330556", "30671561"]}, {"Citation": "Silvestre M.P., Rodrigues A.M., Canh\u00e3o H., Marques C., Teixeira D., Calhau C., Branco J. Cross-Talk between Diet-Associated Dysbiosis and Hand Osteoarthritis. Nutrients. 2020;12:3469. doi: 10.3390/nu12113469.", "ArticleIdList": ["10.3390/nu12113469", "PMC7696908", "33198220"]}, {"Citation": "Lee S.H., Kwon J.Y., Jhun J., Jung K., Park S.-H., Yang C.W., Cho Y., Kim S.J., Cho M.-L. Lactobacillus acidophilus ameliorates pain and cartilage degradation in experimental osteoarthritis. Immunol. Lett. 2018;203:6\u201314. doi: 10.1016/j.imlet.2018.07.003.", "ArticleIdList": ["10.1016/j.imlet.2018.07.003", "30003932"]}, {"Citation": "Ahmad N., Ansari M.Y., Bano S., Haqqi T.M. Imperatorin suppresses IL-1\u03b2-induced iNOS expression via inhibiting ERK-MAPK/AP1 signaling in primary human OA chondrocytes. Int. Immunopharmacol. 2020;85:106612. doi: 10.1016/j.intimp.2020.106612.", "ArticleIdList": ["10.1016/j.intimp.2020.106612", "32450530"]}, {"Citation": "Lu C., Li Y., Hu S., Cai Y., Yang Z., Peng K. Scoparone prevents IL-1\u03b2-induced inflammatory response in human osteo-arthritis chondrocytes through the PI3K/Akt/NF-\u03baB pathway. Biomed. Pharmacother. 2018;106:1169\u20131174. doi: 10.1016/j.biopha.2018.07.062.", "ArticleIdList": ["10.1016/j.biopha.2018.07.062", "30119184"]}, {"Citation": "Qiao Z., Tang J., Wu W., Liu M. Acteoside inhibits inflammatory response via JAK/STAT signaling pathway in osteoarthritic rats. BMC Complement. Altern. Med. 2019;19:1\u20138. doi: 10.1186/s12906-019-2673-7.", "ArticleIdList": ["10.1186/s12906-019-2673-7", "PMC6781407", "31590658"]}, {"Citation": "Al-Afify A.S., El-Akabawy G., El-Sherif N.M., El-Safty F.E.-N.A., El-Habiby M.M. Avocado soybean unsaponifiables ameliorates cartilage and subchondral bone degeneration in mono-iodoacetate-induced knee osteoarthritis in rats. Tissue Cell. 2018;52:108\u2013115. doi: 10.1016/j.tice.2018.05.001.", "ArticleIdList": ["10.1016/j.tice.2018.05.001", "29857819"]}, {"Citation": "Shin H.J., Park H., Shin N., Kwon H.H., Yin Y., Hwang J.A., Kim S.I., Kim S.R., Kim S., Joo Y., et al. p47phox siR-NA-Loaded PLGA nanoparticles suppress ROS/oxidative stress-induced chondrocyte damage in osteoarthritis. Polymers. 2020;12:443. doi: 10.3390/polym12020443.", "ArticleIdList": ["10.3390/polym12020443", "PMC7077645", "32069893"]}, {"Citation": "Hoshi H., Akagi R., Yamaguchi S., Muramatsu Y., Akatsu Y., Yamamoto Y., Sasaki T., Takahashi K., Sasho T. Effect of inhibiting MMP13 and ADAMTS5 by intra-articular injection of small interfering RNA in a surgically induced osteoarthritis model of mice. Cell Tissue Res. 2017;368:379\u2013387. doi: 10.1007/s00441-016-2563-y.", "ArticleIdList": ["10.1007/s00441-016-2563-y", "28120109"]}, {"Citation": "Chen L.X., Lin L., Wang H.J., Wei X.L., Fu X., Zhang J.Y., Yu C.L. Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. Osteoarthr. Cartil. 2008;16:174\u2013184. doi: 10.1016/j.joca.2007.06.006.", "ArticleIdList": ["10.1016/j.joca.2007.06.006", "17686636"]}, {"Citation": "Kong Y., Zhang Y., Zhao X., Wang G., Liu Q. Carboxymethyl-chitosan attenuates inducible nitric oxide synthase and promotes interleukin-10 production in rat chondrocytes. Exp. Ther. Med. 2017;14:5641\u20135646. doi: 10.3892/etm.2017.5258.", "ArticleIdList": ["10.3892/etm.2017.5258", "PMC5740727", "29285104"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "1", "Day": "31"}, {"Year": "2021", "Month": "2", "Day": "25"}, {"Year": "2021", "Month": "3", "Day": "4"}, {"Year": "2021", "Month": "4", "Day": "3", "Hour": "1", "Minute": "4"}, {"Year": "2021", "Month": "4", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "5", "Day": "20", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "3", "Day": "7"}], "PublicationStatus": "epublish", "ArticleIdList": ["33800057", "PMC7962130", "10.3390/ijms22052697", "ijms22052697"]}}], "PubmedBookArticle": []}